Yahoo · Sep 22, 2026
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
IN
NASDAQ · INSP
Inspire Medical Systems, Inc.
Healthcare · Medical - Devices
$69.36
Up+$0.64 (+0.92%)
Updated Oct 1, 2026, 4:42 PM
SID Score
4.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.05B
- P/E ratio
- 76.09
- Dividend yield
- 0.00%
- 52-week range
- $38.91 – $147.03
- Volume
- 1M
- Avg. volume
- 1.3M
Price performance · INSP
INSP price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 30, 2026
INSP closed at $69.36 after 20 trading sessions, up 9.97% for the selected period.
- Last close
- $69.36
- Period change
- +9.97%
- Period low
- $62.14
- Period high
- $76.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 30, 2026 | $73.09 | $73.25 | $68.50 | $69.36 | 1M |
| Sep 29, 2026 | $69.78 | $73.24 | $69.18 | $73.18 | 873.52K |
| Sep 28, 2026 | $70.83 | $70.93 | $69.5868 | $70.00 | 442.26K |
| Sep 25, 2026 | $68.65 | $70.98 | $68.13 | $70.50 | 609.84K |
| Sep 24, 2026 | $69.11 | $70.58 | $68.65 | $68.81 | 580.64K |
| Sep 23, 2026 | $71.38 | $72.10 | $68.15 | $69.06 | 729.57K |
| Sep 22, 2026 | $75.32 | $76.10 | $71.19 | $71.30 | 1.12M |
| Sep 21, 2026 | $76.50 | $77.26 | $74.9201 | $75.72 | 1.08M |
| Sep 18, 2026 | $72.29 | $78.7999 | $71.43 | $76.78 | 2.13M |
| Sep 17, 2026 | $73.54 | $75.36 | $72.74 | $72.74 | 564.18K |
| Sep 16, 2026 | $73.17 | $75.49 | $72.23 | $72.75 | 845.86K |
| Sep 15, 2026 | $73.80 | $75.265 | $72.7153 | $74.60 | 838.11K |
| Sep 14, 2026 | $72.14 | $75.29 | $71.845 | $74.32 | 1.17M |
| Sep 11, 2026 | $69.88 | $74.95 | $69.87 | $73.00 | 1.4M |
| Sep 10, 2026 | $64.35 | $68.50 | $64.02 | $68.12 | 1.14M |
| Sep 9, 2026 | $62.43 | $67.7229 | $62.009 | $66.48 | 1.2M |
| Sep 8, 2026 | $64.03 | $64.12 | $61.61 | $62.14 | 621.54K |
| Sep 4, 2026 | $61.00 | $63.43 | $60.00 | $63.08 | 425.72K |
| Sep 3, 2026 | $63.70 | $63.755 | $61.65 | $62.14 | 398.86K |
| Sep 2, 2026 | $61.24 | $64.335 | $61.19 | $63.07 | 413.01K |
Latest INSP news
The latest Smart Investors Daily articles mentioning INSP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INSP research
Overview
Company profile and research snapshot.
Company profile
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $139.92
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | Freedom Capital Markets | Buy | — |
| Sep 11, 2026 | Stifel | Buy | — |
| Aug 4, 2026 | Evercore ISI Group | In-Line | — |
| Aug 4, 2026 | Piper Sandler | Neutral | — |
| Aug 4, 2026 | Baird | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 21, 2026
Microsoft To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for INSP, SECZ, CLF and WAT, while cutting targets for CRDO, CL and TTMI; ratings remained unchanged.
Benzinga · Sep 21, 2026
Freedom Capital Markets Maintains Buy on Inspire Medical Systems, Raises Price Target to $97
Freedom Capital Markets analyst Keith Hinton maintains Inspire Medical Systems (NYSE:INSP) with a Buy and raises the price target from $71 to $97.
Yahoo · Sep 18, 2026
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
